High-Quality Enterprise Management Promotes Sustainable Business Development
优质企业管理 推动企业可持续发展
Sinopharm Group Co., Ltd.
INTRODUCTION
The board of directors is the core of the Group’s corporate governance structure. On this basis, they give full play to specialisation, the leading role and supervision function of the high-level company board of directors and various professional committees, carefully deploying various development regulations, actively build and optimise the corporate governance system. In 2019, the Group continued to improve system construction, strengthening risk management and control, paying close attention to safety and quality, fulfill social responsibilities, and stepping up the implementation of the Group’s quality and efficiency of various work to consolidate the business foundation of the company’s long-term high-quality development, and strongly promote the company’s core business comprehensive service capabilities for upgrade.
FRAMEWORK AND STRATEGY
Under the strong support of the Group’s shareholders and the strategic guidance of the board of directors, the Group continuously optimises their development strategy. Accelerating the overall transformation and upgrading of business, improve the quality of operations, and strengthen the efficiency of corporate governance. The Group regularly review environmental protection, social and governance strategies, including assessment and determination of environmental impact, social and corporate governance related risks, and efforts to improve related. The governance system and management and control process ensures appropriate and effective environmental, social and governance risk management and internal monitoring are in place.ACHIEVEMENT AND IMPACT
Inspection and supervision by government regulatory agencies were done to ensure corporate governance is adhered. In 2019, the State Control Headquarters passed the Shanghai Market Supervision and Administration Bureau five times for special management of drugs and fentanyl to ensure no major and serious defects and the inspection pass rate is 100%. To add on to that, subsidiaries within the Group’s department received a total of 2,115 external inspections. There were no serious non-conformances, all of which met the requirements. The Group has bagged multiple awards, namely, the Golden Bauhinia Award and the 2019 China Financing Awards, the Group won the “Best Listed Company” Award and was ranked 25th on Fortune China 500 in 2019, while being ranked 32nd in the Top 100 Hong Kong Stocks of Hong Kong Listed Companies. Lastly, the Group has also achieved outstanding results in personnel training and employee development, and is committed to do their best to provide employees with safe and healthy working environment while trying to create a harmonious humanistic environment.FUTURE DIRECTION
The Company will always incorporate their mission, performing strategic planning, implementing operational safety, strengthening quality control and improving customers’ satisfaction, promoting energy conservation and environmental protection and other aspects as the first developing direction of corporate governance. The Company hopes to further optimise their business governance system,strengthen business operation efficiency, perform corporate social responsibilities, continuously strengthen public trust in the efficiency of state-controlled governance, and enhance the corporate image and responsibility, make continuous efforts to build a responsible leading comprehensive medical service provider.
Sinopharm Group Co. Ltd., was established in January 2003, is a core
subsidiary of China National Pharmaceutical Group Co., Ltd., the largest
wholesaler and retailer of pharmaceutical and healthcare products and
medical devices and a leading supply-chain service provider in the PRC.
